Physician profile
Jay Weissbluth
NPI 1659376119
$7,729.34
in general payments reported to CMS, 2019-2025
34 companies · $793 in 2025
The $793 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,326 · 2020: $684 · 2021: $1,412 · 2022: $1,166 · 2023: $880 · 2024: $1,468 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,140.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,349.28 | 2019-2025 | Mavyret, Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,748.47 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $568.99 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $404.46 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $281.33 | 2024-2025 | Zenpep |
| Pfizer INC. | $249.49 | 2019-2025 | |
| Celgene Corporation | $243.01 | 2021-2024 | Zeposia |
| Braintree Laboratories, INC. | $232.98 | 2019-2023 | Sutab |
| Nestle Healthcare Nutrition INC. | $229.26 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $184.61 | 2019-2025 | Entyvio, Eohilia |
| Redhill Biopharma INC. | $157.99 | 2020-2022 | |
| Ardelyx, INC. | $112.58 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $108.58 | 2023-2024 | Dificid |
| Allergan, INC. | $98.15 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $91.67 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $91.35 | 2019 | |
| Janssen Biotech, INC. | $87.41 | 2024-2025 | Tremfya, Stelara |
| Shield Therapeutics INC | $77.56 | 2024-2025 | |
| Vivus LLC | $59.30 | 2021-2022 | |
| Celltrion USA INC. | $49.50 | 2025 | Vegzelma |
| Lilly USA, LLC | $37.34 | 2025 | Omvoh |
| Exact Sciences Corporation | $28.59 | 2025 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $26.93 | 2022 | |
| Viiv Healthcare Company | $24.52 | 2025 | Apretude |
| E.R. Squibb & Sons, L.L.C. | $23.81 | 2021 | |
| Olympus America INC. | $23.17 | 2023 | Single Use Electrosurgical Snare Sd-400 |
| Concordia Pharmaceuticals INC. | $21.29 | 2019 | |
| Shire North American Group INC | $20.50 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $19.73 | 2025 | Iqirvo |
| Novo Nordisk INC | $19.44 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $16.97 | 2020 | |
| Medline Industries Lp | $14.49 | 2019 | |
| Qol Medical, LLC | $13.67 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $12.92 | 2024 | Sureclip |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Weissbluth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.